肿瘤细胞治疗研究
ALL SOURCES
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective
结果显示，mRNA BNT162b2 疫苗在免疫功能低下患者中是安全的。
Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies.
与未接种过疫苗的受种者相比，这些患者对疫苗接种表现出异质性的适应性免疫应答和固有免疫应答，体液免疫应答较低、固有免疫细胞因子应答减弱。
Herpes Zoster in Hematological Disorders: Pathogenesis, Risk Stratification, and Emerging Strategies for Prevention and Immunization.
血液系统疾病患者尤其易患 HZ。
Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoi
仅有 25% 的 HSCT/CAR-T 受者在接种一剂后产生了 nAbs，其滴度在接种第一剂和第二剂后分别比医护人员低 167 倍和 7 倍。
Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was alter
结果显示，HSCT受者对SARS-CoV-2疫苗的体液和细胞适应性免疫应答均受到皮质类固醇治疗的显著抑制。对疫苗的特异性应答受到HSCT与接种疫苗之间间隔时间的显著影响。HSCT后最早5个月接种疫苗即可产生良好应答。对疫苗的免疫应答与年龄、性别、HSC供受者之间的HLA匹配或髓系恶性肿瘤类型无关。疫苗效力取决于HSCT后6个月时重建良好的CD4 + T细胞。
共 5 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
